AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

https://www.marketbeat.com/instant-alerts/nasdaq-axsm-a-buy-or-sell-right-now-2020-12/

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression https://www.globenewswire.com/news-release/2020/12/02/2138129/0/en/Axsome-Therapeutics-Announces-Positive-Results-from-the-COMET-TRD-Trial-of-AXS-05-in-Patients-with-Treatment-Resistant-Depression.html Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial improvement in functioning achieved by 53% of patients at 2 weeks, 64% of patients at 6 weeks (Sheehan Disability Scale), and sustained with long-term treatment Marked or moderate improvement in depression achieved by 49% of patients at 2 weeks, 78% of patients at 6 weeks (Clinical Global Impression), and sustained with long-term treatment ...

👍

http://www.globenewswire.com/news-release/2020/12/01/2137234/0/en/Axsome-Therapeutics-Announces-Positive-Efficacy-and-Safety-Results-from-Phase-3-COMET-Long-Term-Trial-and-COMET-AU-Trial-of-AXS-05-in-Major-Depressive-Disorder.html

Axsome Therapeutics EPS misses by $0.03 https://seekingalpha.com/news/3632021-axsome-therapeutics-eps-misses-0_03 Axsome Therapeutics (NASDAQ:AXSM): Q3 GAAP EPS of -$0.61 misses by $0.03. Cash of $202.4 M. Axsome believes that its cash at September 30, 2020 along with the committed capital from its $225M term loan facility will be sufficient to fund the Company’s anticipated operations, based on its current operating plans, into at least 2024.

Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update https://www.globenewswire.com/news-release/2020/11/05/2120907/0/en/Axsome-Therapeutics-Reports-Third-Quarter-2020-Financial-Results-and-Provides-Business-Update.html COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submissions for AXS-05 in depression expected in January 2021, and for AXS-07 in migraine expected in 1Q 2021 Launch readiness activities progressing with buildout of Digital-Centric Commercialization (DCC) platform Efficacy results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD, and suicidal ideation, on track for 4Q 2020 Efficacy results from MOVEMENT Phase 3 open-label trial of AXS-07 in migraine expected in 4Q 2020 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation on track for initiation in 4Q 2020 Phase 3 trial of AXS-12 in narcolepsy on track for initiation in 1Q 2021 FDA meeting for AXS-14 in fibromyalgia scheduled for 1Q 2021 ...

Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization Platform http://www.globenewswire.com/news-release/2020/11/04/2119995/0/en/Axsome-Therapeutics-and-Veeva-Systems-Partner-to-Build-Axsome-s-Digital-Centric-Commercialization-Platform.html

Aber was hat das jetzt mit Axsome zu tun 🤔? Ich muss mir doch eh bei jedem Wert selbst ein Bild machen - egal, was andere von sich geben.

Interessant wie Adler hier lammfromm vor sich hin redet und den großen mersias gibt, wenn ich doch die letzte Zeit beobachte was er für einen m.üll im Medigen Forum schreibt. Arbeitslosigkeit sollte nicht mit finanzieller unabhängigkeit verwechselt werden!

Sorry, hatte Acelrx überlesen 🙃🙂 Aber auch die wird ihren Weg machen

Deshalb hat seeking alpha sie auch noch mal unter die Lupe genommen 😉: https://seekingalpha.com/article/4377404-play-on-axsome-therapeutics The Play On Axsome Therapeutics

Acelrx wird auch bald hoch fliegen

👍

100€ Marke.....

Die 100€ kommt zurück, keine Frage!! ✌️

Bank of America takes a bear call on Axsome on disappointment expectations https://seekingalpha.com/news/3618146-bank-of-america-takes-bear-call-on-axsome-on-disappointment-expectations Bank of America initiated Axsome Therapeutics (AXSM -5.6%) with Underperform, PT $66; on the contrary, Wall St. Analysts rating is Very Bullish. In the past one year, the stock has multiplied 2.5 times vs. a drop of 26% on YTD basis. Analyst Ashwani Verma notes that his contrarian call is driven by expectations of disappointment from the company's 2021 primary care launches targeting depression and migraine because of their "undifferentiated" characteristics and "saturated" target markets. ...